Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)Executive Officer Retention Bonus Opportunity

On January 21, 2022, the Compensation Committee of the Board of Directors of GlycoMimetics, Inc. (the "Company") awarded potential cash retention bonuses to certain employees of the Company, including the Company's executive officers other than the Company's Chief Executive Officer. Each of Brian Hahn, the Company's Chief Financial Officer, and Armand Girard, the Company's Chief Business Officer, will have the opportunity to earn a bonus of up to 60% of the respective officer's current base salary, and John Magnani, the Company's Chief Scientific Officer, will have the opportunity to earn a bonus of up to 20% of his current base salary. Of the total bonus opportunity, 40% is payable in a lump sum on August 1, 2022 and the remaining 60% is payable in a lump sum on August 1, 2023, in each case subject to the officer's continued employment with the Company on a full-time basis through the applicable bonus payment date. The potential cash retention bonuses described above are in addition to each officer's annual bonus opportunity under their respective current employment agreements with the Company.




Item 8.01Other Events.

On January 21, 2022, the Compensation Committee of the Board adopted an amendment to the GlycoMimetics, Inc. Inducement Plan (the "Inducement Plan") to increase the number of shares of common stock reserved for issuance under the Inducement Plan from 2,000,000 shares to 3,000,000 shares, subject to adjustment for stock dividends, stock splits, or other changes in the Company's capital structure.











                                       2

© Edgar Online, source Glimpses